International Journal of Medical Sciences

Impact factor
2.399

14 December 2017

ISSN 1449-1907 News feeds of published articles

My Manuscript | My Account

Journal of Biomedicinenew

Theranostics

Journal of Cancer

Oncomedicine

International Journal of Biological Sciences

Journal of Genomics

Journal of Bone and Joint Infection (JBJI)

Nanotheranostics

PubMed Central Indexed in Journal Impact Factor

Int J Med Sci 2015; 12(8):674-679. doi:10.7150/ijms.12450

Research Paper

Arsenic Trioxide Activate Transcription of Heme Oxygenase-1 by Promoting Nuclear Translocation of NFE2L2

Zhen Yue1#, Lingzhi Zhong1, 3#, Yan Mou1, 2, Xiaotong Wang1, Haiying Zhang1, Yang Wang1, Jianxin Xia2, Ronggui Li1✉, Zonggui Wang2✉

1. Key Laboratory of Pathobiology, Ministry of Education, Norman Bethune College of Medicine, Jilin University, Changchun, China
2. The Second Hospital of Jilin University, Changchun, P.R. China.
3. Current address: Institute of Basic Medical Sciences, College of Life Science, Chinese PLA General Hospital, Beijing 100853, China
#These authors contributed equally to this work.

Abstract

In a previous study, we found that induced expression of Heme Oxygenase-1 (HO-1) is responsible for the resistance of human osteosarcoma MG63 cells to the chemotherapeutic agent arsenic trioxide (ATO). The present study was aimed at investigating the molecular mechanisms underlying the induction of HO-1 that occurs after exposure of MG63 cells to ATO. First, using RT-QPCT and Western-blot, we found that ATO strongly induced the expression of heme oxygenase-1 (HO-1) in these human osteosarcoma cells. Then by analyzing HO-1 mRNA of MG63 cells exposed to ATO in the presence and absence of a transcription inhibitor Actinomycin-D (Act-D), we demonstrated that ATO activates HO-1 expression in MG63 cells by regulating the transcription of the gene. Finally, through the analysis of the NFE2L2 protein levels among the total cellular and nuclear proteins by Western-blot and Immunocytochemical staning, we determined that ATO enhanced the nuclear translocation of nuclear factor erythroid 2-like 2 (NFE2L2), also known as Nrf2. From these results we have concluded that transcription activation of HO-1 resulting from the nuclear translocation of NFE2L2 is the underlying molecular mechanism for its high induction, which, in turn, is responsible for the resistance of human osteosarcoma cells to ATO treatment.

Keywords: Arsenic trioxide, heme oxygenase-1, nuclear factor erythroid 2-like 2, osteosarcoma, Nuclear Translocation

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Yue Z, Zhong L, Mou Y, Wang X, Zhang H, Wang Y, Xia J, Li R, Wang Z. Arsenic Trioxide Activate Transcription of Heme Oxygenase-1 by Promoting Nuclear Translocation of NFE2L2. Int J Med Sci 2015; 12(8):674-679. doi:10.7150/ijms.12450. Available from http://www.medsci.org/v12p0674.htm